WBB Securities Initiates Coverage On enGene Therapeutics with Buy Rating, Announces Price Target of $21.5
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
WBB Securities analyst Karen Sterling initiates coverage on enGene Therapeutics (NASDAQ:ENGN) with a Buy rating and announces Price Target of $21.5.
WBB Securities analyst Karen Sterling initiates coverage on enGene Therapeutics (NASDAQ:ENGN) with a Buy rating and announces Price Target of $21.5.